Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of MMV371 Long-Acting Injection in Healthy Adults and Adolescents
NCT07548021Phase 1Not yet recruiting
- Sponsor
- Medicines for Malaria Venture
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CBE161 in malaria (8 arms), sponsored by Medicines for Malaria Venture. Primary endpoints: Incidence of adverse events at 24 weeks, Incidence of grade 2 or greater injection site reactions at 24 weeks and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
CBE161
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07548021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07548021.